TWD
DNLI icon

True Wealth Design’s Denali Therapeutics DNLI Stock Holding History

True Wealth Design’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.26K Buy
88
+31
+54% +$637 ﹤0.01% 1634
2026
Q1 		$1.09K Buy
57
+1
+2% +$20 ﹤0.01% 1778
2025
Q4 		$925 Hold
56
– – ﹤0.01% 1732
2025
Q3 		$814 Hold
56
– – ﹤0.01% 1823
2025
Q2 		$784 Buy
+56
New +$788 ﹤0.01% 1565

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

True Wealth Design's DNLI Position: Q2 2026 in Review

True Wealth Design increased its Denali Therapeutics (DNLI) stake by 54% in Q2 2026, buying an estimated $637 and bringing the position to 88 shares worth $2.26K. The position accounts for ﹤0.01% of the portfolio, ranked #1634.

True Wealth Design first reported a position in DNLI in Q2 2025 and has held it in 5 quarters since. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • True Wealth Design held 88 shares of Denali Therapeutics worth $2.26K as of Q2 2026.
  • True Wealth Design bought 31 Denali Therapeutics shares in Q2 2026, an estimated $637.
  • Denali Therapeutics made up ﹤0.01% of True Wealth Design's portfolio in Q2 2026, its #1634 holding.
  • True Wealth Design first reported a position in Denali Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on True Wealth Design's 13F filing for Q2 2026, filed 16 Jul 2026.